Hosted on MSN21h
Wolfe Research Downgrades Matson (MATX)
Fintel reports that on November 18, 2024, Wolfe Research downgraded their outlook for Matson (NYSE:MATX) from Outperform to ...
bovnews1h
Why Did Wolfe Research Give Gilead Sciences, Inc. (GILD) Stock Outperform Rating?
On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $88.4 which represents a decrease of $-3.71 or -4.03% from the prior close of $92.11. The stock opened at $91.71 and ...
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wolfe Research
Wolfe Research upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) to a strong-buy rating in a report ...
Fintel on MSN2d
Wolfe Research Initiates Coverage of Johnson & Johnson (JNJ) with Outperform Recommendation
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Johnson & Johnson (NYSE:JNJ) with a Outperform ...
Wolfe Research starts Regeneron at Outperform, sees ‘attractive entry point’
Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had ...
Wolfe Research starts Moderna at Underperform, sees limited upside opportunity
Wolfe Research analyst Alexandria Hammond initiated coverage of Moderna (MRNA) with an Underperform rating and $40 price target Moderna may ...
bovnews2h
AbbVie Inc (ABBV) Stock: More Strategic Than Meets the Eye
On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $164.99 which represents a decrease of $-4.64 or -2.74% from the prior close of $169.63. The stock opened at $169.63 and touched a ...
Seeking Alpha6d
Argenx upgraded at Wolfe on myasthenia gravis dominance
Argenx (NASDAQ:ARGX) shares trended higher on Tuesday after Wolfe Research upgraded the Dutch biotech to Outperform from Peer Perform, citing higher confidence in the company's dominance in the ...
ETF Daily News4d
Wolfe Research Forecasts Strong Price Appreciation for Occidental Petroleum (NYSE:OXY) Stock
Occidental Petroleum (NYSE:OXY – Get Free Report) had its target price lifted by equities research analysts at Wolfe Research from $73.00 to $75.00 in a report released on Tuesday. The firm pres ...
Nasdaq6d
Wolfe Research Downgrades Alnylam Pharmaceuticals (LSE:0HD2)
Fintel reports that on November 12, 2024, Wolfe Research downgraded their outlook for Alnylam Pharmaceuticals (LSE:0HD2) from Peer Perform to Underperform. There are 1,155 funds or institutions ...
Investing4d
Wolfe Research initiates Repligen shares coverage with Peerperform rating
On Thursday, Wolfe Research began coverage on shares of Repligen (NASDAQ:RGEN) Corporation (NASDAQ:RGEN), a leading bioprocessing company, with a Peerperform rating. The firm highlighted Repligen's ...
Nasdaq6d
Alnylam cut to Underperform at Wolfe Research amid Amvuttra expansion
Wolfe Research downgraded Alnylam (ALNY) to Underperform from Peer Perform with a $205 price target The firm cites expectations that the company will expand its approved Amvuttra into the much ...